Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Texas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Texas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Texas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jason Ysasaga (NPI 1356310734)

Field	Value
Entity Type	Individual
Organization	Jason Ysasaga
Address	7411 Wallace Blvd
City	Amarillo
State	TX
ZIP	79106
Taxonomy	Ophthalmology Physician
NPI Enumerated	March 16, 2006

Payer Source	Total Paid
Medicare	$9.9M
Medicaid	$0

Key Findings

This provider’s Medicare revenue is heavily driven by intravitreal drug therapy: J2777 (faricimab) accounts for $4.8M revenue and 48.6% of total Medicare revenue, J3490 (unclassified drugs) contributes $1.7M (17.5%), and J2781 (pegcetacoplan) adds $664.2K (6.7%); together these three codes account for 72.8% of the provider’s total Medicare revenue, indicating a highly concentrated, drug‑focused service line. These numbers point to an outpatient retina practice model centered on high-volume injectable therapeutics.

Top‑code concentration is acute: the precomputed top‑3 share is 72.8% of Medicare revenue, which signals material dependence on a small set of high‑cost drug and injection codes. That level of revenue concentration suggests that changes in utilization patterns, drug availability, or reimbursement for those few codes would meaningfully affect overall Medicare revenue.

The payer mix is effectively single‑payer Medicare: lifetime Medicare revenue is $9.9M and there is no Medicaid billing on file, so this provider operates without recorded Medicaid volume and is highly Medicare‑dependent. For payers and network planners, this profile indicates limited Medicaid exposure and a need to evaluate Medicare policy and reimbursement shifts as the primary financial risk.

Competitive standing for specialty drug delivery is nationally prominent: J2777 ranks #7 of 2039 providers nationally (100th percentile; extreme outlier), J2781 ranks #4 of 490 providers (99th percentile; extreme outlier), and J3490 ranks #45 of 2838 providers (98th percentile; described here as typical/unremarkable for that code). These ranks indicate the provider is a major national outlier for faricimab and pegcetacoplan administration and occupies a high percentile for drug‑related billing relative to peers.

High volumes of advanced retinal imaging and angiography support the clinical footprint of a retina specialty practice: 92235 shows 4K claims and $408.2K revenue (ranks #1 of 2192; 100th percentile; extreme outlier), 92240 shows 1.5K claims and $211.7K revenue (ranks #1 of 39; 100th percentile; extreme outlier), and 92134 shows 4.9K claims and $141.5K revenue (ranks #54 of 26868; 100th percentile; extreme outlier). The mix of high‑rank imaging codes plus injection codes implies on‑site diagnostic capacity (FA/ICG angiography and OCT) that supports frequent intravitreal treatment visits.

The provider also performs surgical retina procedures in addition to injections: 67042 ($64.7K, rank #51 of 1087; 95th percentile; notably above typical), 67041 ($54.1K, rank #13 of 461; 97th percentile; notably above typical), and 67228 ($43K, rank #3 of 648; 100th percentile; extreme outlier) indicate a nontrivial surgical retina caseload. This surgical activity complements the injection and imaging volume and suggests a practice that manages a broad spectrum of retinal disease from diagnostics and medical therapy to operative interventions.

The provider has a long tenure in Medicare billing, with NPI enumeration dated 2006-03-16 (~20 years ago), which together with sustained high volumes and top‑percentile national ranks implies an established, stable specialty practice in Amarillo, TX. For competitor and network analysis, that tenure plus demonstrated capacity for high‑volume drug administration and advanced diagnostics positions the provider as an entrenched retina operator in the market.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

33 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2777	Injection, faricimab‑svoa, 0.1 mg	165,860	$30	$4.8M
J3490	Unclassified drugs	990	$1,760	$1.7M
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	5,540	$120	$664.2K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	5,020	$90	$431.5K
92235	The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken…	4,040	$100	$408.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	4,610	$90	$401.2K
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	1,860	$170	$320.9K
92240	The provider uses a special dye, indocyanine–green (ICG), to take photographs of the vessels of the inner eye similar to that done for codes 92230/92235, which use fluorescein dye. He interprets the…	1,510	$140	$211.7K
J2778	Injection, ranibizumab, 0.1 mg	830	$180	$147.7K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	4,880	$30	$141.5K

Showing 1–10 of 33

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 33 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Texas Distribution

Jason Ysasaga — 15 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Texas

Full comparison — all codes billed, vs. state median

33 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	197	210	610	$690	$694.9K
J2777	3	140	7,470	$30	$479.2K
J2778	36	80	630	$180	$345.3K
Q5124	1	10	1,140	$170	$183.8K
J2781	1	50	720	$120	$131.9K
67028	1	290	510	$90	$73K
92240	1	10	230	$140	$66.9K
J3490	4	350	60	$480	$54.4K
67042	9	90	20	$1,150	$41.3K
J7312	3	40	200	$150	$40.8K

Showing 1–10 of 33

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jason Ysasaga, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ryan Rush	TX	Ophthalmology Physician	$9.7M	$0
Christopher Fisher	OK	Internal Medicine Physician	$7.6M	$0
Antonio Aragon	TX	Ophthalmology Physician	$7.3M	$0
Brian Phelps	OK	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Christopher Fuller	TX	Ophthalmology Physician	$3.6M	$0
Constantine Saadeh	TX	Rheumatology Physician	$3.6M	$0
Michael Hood	OK	Retina Specialist (Ophthalmology) Physician	$3.5M	$0
Jim Lu	IL	Anatomic Pathology Physician	$2.7M	$584.1K
Ashok Reddy	NM	Ophthalmology Physician	$3.2M	$0
Joseph Wolcott	TX	Undersea and Hyperbaric Medicine (Preventive Medicine) Physician	$3.1M	$0

Nearby Providers

Other providers in the same ZIP code as Jason Ysasaga, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Northwest Texas Healthcare System Inc	TX	General Acute Care Hospital	$0	$44.8M
Amarillo Independent School District	TX	Local Education Agency (LEA)	$0	$17.5M
Epic Health Services, Inc.	TX	Home Health Agency	$0	$13.8M
Britkare Home Medical Of Texas Ltd	TX	Durable Medical Equipment & Medical Supplies	$0	$12.6M
Texas Panhandle Mental Health Mental Retardation	TX	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$11.6M
Apc-amarillo Surgical Operating Company, LLC	TX	Ambulatory Surgical Clinic/Center	$4.8M	$380
Amarillo Cataract And Eye Surgery Center Ltd	TX	Ophthalmologic Surgery Clinic/Center	$3.8M	$77.7K
Janet Schwartzenberg	TX	Rheumatology Physician	$2.6M	$0
James Stafford	TX	Radiation Oncology Physician	$1.5M	$0
Psg Surgery Center LLC	TX	Ambulatory Surgical Clinic/Center	$1.3M	$0

Jason Ysasaga — Billing Profile & Reimbursement Data

Sign up for Jason Ysasaga — Billing Profile & Reimbursement Data policy alerts

Jason Ysasaga — Billing Profile & Reimbursement Data

Sign up for Jason Ysasaga — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References